An Open-labelled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy.

Trial Profile

An Open-labelled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Zalutumumab (Primary)
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ZALUTE
  • Sponsors Genmab
  • Most Recent Events

    • 22 Sep 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 22 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Oct 2010 Genmab has received preliminary positive feedback from the European and US regulatory authorities based on results from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top